Silexion Initiates Phase 2/3 Pancreatic Cancer Trial, Reports Q2 Results
SLXN is trading near its 52-week low of $0.411 (0.8% above the low).
Summary
Silexion reported Q2 2026 financials and confirmed the Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer began at Tel Aviv Sourasky Medical Center on July 29, 2026. This follows German BfArM approval in June and Israeli approval earlier. The company also closed a $2.5 million public offering to fund the trial. With a market cap near $0.5M and stock at $0.41, the trial initiation is a major operational milestone, though financing remains tight. Watch for first patient dosing and additional site activations in coming months.
At the time of this announcement, SLXN was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489K. The 52-week trading range was $0.41 to $80.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.